Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Scaling up iPSC Expansion and Differentiation using Recombinant Bioemulsions

Project description

Engineering recombinant protein bioemulsions to improve induced pluripotent stem cells’ scalability

Induced pluripotent stem cells (iPSCs), which can expand in cultures and differentiate into various cell types, are a promising tool for regenerative medicine, disease modelling and drug discovery. However, issues concerning scalability, cost, quality and safety inhibit their wider use in clinical applications. While bioemulsions show promise in sustaining iPSC culture, current protein and polymer nanosheet technologies do not meet compliance protocols for widespread manufacture and use. To address this, the ERC-funded uPSCale project aims to develop recombinant protein nanosheets that will stabilise biomedical-grade oil microdroplets, enabling scalable production of bioemulsions in line with regulatory protocols. The resulting bioemulsions and related technology will be validated and optimised in cooperation with industry partners to ensure their safety and stability.

Objective

Advances in stem cell technologies have revolutionised cell therapy and advanced in vitro models, but remain limited by our ability to scale up and automate cell manufacturing. In particular, induced pluripotent stem cell (iPSC) expansion and differentiation require complex processing protocols that are preventing the wider deployment of associated technologies to the clinic and industry. Although solid and hydrogel microcarriers have displayed potential in addressing this challenge, they present hurdles to the processing and separation from cell products, leading to contamination of the generated cells, the poor control of their phenotype and high production costs. Developing cost-effective, scalable, and regulatory-compliant platforms for culturing, differentiating and processing iPSCs, while circumventing reliance on solid substrates and microcarriers, remains critical for advancing cell manufacturing and will significantly impact the sustained growth of associated biotech markets. To mitigate contamination risks, streamline bioprocessing, and reduce associated costs, bioemulsions have emerged as promising alternatives. Despite their demonstrated performance in a growing range of cellular contexts, current underpinning protein and polymer nanosheet technologies raise concerns regarding regulatory compliance, for broad application in regenerative medicine. We propose the engineering of recombinant protein nanosheets for the stabilisation of biomedical grade oil microdroplets, that will tackle these challenges and allow the production of bioemulsions in a scalable format, aligned with regulatory expectations. The ability of the resulting bioemulsions to sustain the culture of iPSCs and their differentiation into defined lineages will be validated and this technology will be de-risked, in collaboration with industrial partners aiming to scale up iPSC technologies. This will allow the development of further IP that will support the exploitation of bioemulsions.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

QUEEN MARY UNIVERSITY OF LONDON
Net EU contribution
€ 150 000,00
Address
327 MILE END ROAD
E1 4NS LONDON
United Kingdom
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)